(:SPPI)

Jul 31, 2023 07:27 pm ET
Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc....
Jul 27, 2023 04:01 pm ET
Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc....
Jul 20, 2023 07:00 am ET
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”) announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have each recommended that Spectrum stockholders vote “FOR” the proposal to adopt the Agreement and Plan of Merger (“Merger Agreement”, and such proposal, the “Merger Proposal”) at the upcoming special meeting of stockholders (the “Special Meeting”) on July 27, 2023. Under the terms of the Merger Agreement, Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio”)
Jul 03, 2023 05:15 pm ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates FOCS, ASRT, MDWT, SPPI
NEW YORK, July 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 03, 2023 11:37 am ET
Moore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Jun 30, 2023 03:35 pm ET
SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT). Under the terms of the proposed transaction, shareholders of Spectrum will receive, for each share of Spectrum that they own, 0.1783 shares of Assertio and one contingent value right for the right to receive $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and $0.
May 17, 2023 07:00 am ET
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
May 11, 2023 11:55 am ET
Thinking about buying stock in Maxeon Solar, Evolv, Joby Aviation, Livent, or Spectrum Pharmaceuticals?
NEW YORK, May 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MAXN, EVLV, JOBY, LTHM, and SPPI.
May 09, 2023 07:00 am ET
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update.
May 02, 2023 11:49 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, NATI, SPPI
NEW YORK, May 2, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 01, 2023 05:15 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing Investigations
NEW YORK, May 1, 2023 /PRNewswire/ --
May 01, 2023 12:56 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Apr 29, 2023 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of HOTH, ASRT, SPPI, and CEI
Hoth Therapeutics, Inc. (NASDAQ: HOTH) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of HOTH with Algorithm Sciences, Inc., whereby HOTH shareholders are expected to own...
Apr 28, 2023 01:03 pm ET
Moore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law Firm
NEW YORK, April 28, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Apr 28, 2023 09:17 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPPI, HOTH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Spectrum Pharmaceuticals, Inc....
Apr 27, 2023 06:57 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.
NEW YORK, April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals" or the "Company") (NASDAQ: SPPI), in connection with its acquisition by Assertio Holdings, Inc. (NASDAQ: ASRT) ("Assertio"). Under the merger agreement, the Company's shareholders will receive 0.1783 shares of Assertio common stock for each of their shares, representing implied per-share consideration of $0.89 based upon Assertio's April 26, 2023 closing price of $5.00. Addit
Apr 27, 2023 06:20 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Assertio Holdings, Inc.
NEW YORK, April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), in connection with its proposed merger with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum Pharmaceuticals").
Apr 27, 2023 10:45 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, SPPI, HOTH
NEW YORK, April 27, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apr 26, 2023 05:41 pm ET
ALERT: The M&A Class Action Firm Continues the Investigation of the Merger – MYBF, RXDX, SPPI, TRTN
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Apr 25, 2023 10:29 pm ET
SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT). Under the terms of the proposed transaction, shareholders of Spectrum will receive, for each share of Spectrum that they own, 0.1783 shares of Assertio and one contingent value right for the right to receive $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and $0.
Apr 25, 2023 12:46 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Apr 25, 2023 10:40 am ET
Shareholder Alert: Ademi LLP investigates whether Spectrum Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Assertio
MILWAUKEE, April 25, 2023 /PRNewswire/ -- Ademi LLP is investigating Spectrum (NASDAQ: SPPI) for possible breaches of fiduciary duty and other violations of law in its transaction with Assertio. 
Apr 25, 2023 10:01 am ET
SPPI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Spectrum Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) to Assertio Holdings, Inc. is fair to Spectrum shareholders. Under the terms of the agreement, Spectrum shareholders will receive: (1) 0.1783 shares of Assertio common stock for each share of Spectrum common stock they own; and (2) one contingent value right per Spectrum share for the right to receive $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and $0.10 payable upon ROLVED
Apr 25, 2023 06:00 am ET
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio”), a specialty pharmaceutical company offering differentiated products to patients, and Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum”), a commercial stage biopharmaceutical company...
Mar 22, 2023 08:00 am ET
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022.
Mar 17, 2023 07:00 am ET
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific.
Feb 10, 2023 09:56 am ET
Thinking about buying stock in BP, Vallon Pharmaceuticals, Transocean, Spectrum Pharmaceuticals, or SoundHound AI?
NEW YORK , Feb. 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BP, VLON, RIG, SPPI, and SOUN.
Feb 08, 2023 07:00 am ET
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023.
Feb 03, 2023 11:00 am ET
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Action and to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spectrum common stock between December 6, 2021 through September 22, 2022, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Feb 03, 2023 08:30 am ET
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. (“Spectrum” or “the Company”) (NASDAQ:
Feb 03, 2023 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Feb 02, 2023 08:30 am ET
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. (“Spectrum” or “the Company”) (NASDAQ:
Feb 02, 2023 04:45 am ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Feb. 2, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Feb 01, 2023 05:15 pm ET
SPPI FINAL DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - SPPI
NEW YORK, Feb. 1, 2023 /PRNewswire/ -- 
Feb 01, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Feb. 1, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Jan 31, 2023 07:00 am ET
Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.
Jan 31, 2023 04:45 am ET
SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.
Jan 30, 2023 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders:
Jan 29, 2023 02:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and...
Jan 27, 2023 06:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Jan. 27, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-10677, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired
Jan 27, 2023 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Jan. 27, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Jan 26, 2023 05:06 pm ET
SPECTRUM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) and reminds investors of the February 3, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jan 26, 2023 04:30 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
NEW YORK, Jan. 26, 2023 /PRNewswire/ --
Jan 26, 2023 07:00 am ET
Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on January 26, 2023, Spectrum’s Board of Directors granted an aggregate of 20,833 inducement restricted stock units (“RSUs”) to a commercial non-executive employee who was hired specifically for the launch of ROLVEDON. The award was granted under Spectrum’s 2022 Employment Inducement Incentive Award Plan (“Inducement Plan”) as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of
Jan 26, 2023 04:45 am ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Jan 25, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Jan 24, 2023 04:45 am ET
SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders
NEW YORK, Jan. 24, 2023 /PRNewswire/ --The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.
Jan 23, 2023 10:00 am ET
GNRC, VERU & SPPI Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 23, 2023 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders:
Jan 21, 2023 02:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and...
Jan 20, 2023 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK,, Jan. 20, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Jan 19, 2023 10:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-10677, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired
Jan 19, 2023 05:06 pm ET
SPECTRUM DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) and reminds investors of the February 3, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jan 19, 2023 04:45 am ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Jan 18, 2023 02:45 pm ET
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
NEW YORK, Jan. 18, 2023 /PRNewswire/ --
Jan 18, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Jan. 18, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Jan 17, 2023 04:45 am ET
SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders
NEW YORK, Jan. 17, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.
Jan 16, 2023 05:13 pm ET
Spectrum Pharmaceuticals, Inc.: Please contact the Portnoy Law Firm to recover your losses; February 3, 2023 deadline
The Portnoy Law Firm advises Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) investors that a lawsuit filed on behalf of investors that purchased securities Spectrum, Inc (NASDAQ: SPPI) between December 6, 2021 through...
Jan 16, 2023 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Jan. 16, 2023 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders:
Jan 13, 2023 11:00 pm ET
Kaplan Fox Reminds Investors with Losses in Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) of February 3, 2023 Lead Plaintiff Deadline
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) filed a proposed class action suit in the United States District Court for the Southern District of New York against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NasdaqGS: SPPI),...
Jan 13, 2023 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Jan. 13, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Jan 12, 2023 07:15 pm ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Jan 11, 2023 11:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers.  The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-10677, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired
Jan 11, 2023 03:43 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
NEW YORK, Jan. 11, 2023 /PRNewswire/ --
Jan 11, 2023 04:50 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Jan. 11, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Jan 10, 2023 07:15 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action– SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the “Class Period”), of the...
Jan 10, 2023 04:45 am ET
SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.
Jan 09, 2023 01:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and...
Jan 09, 2023 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders:
Jan 06, 2023 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Jan. 6, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Jan 05, 2023 05:06 pm ET
SPECTRUM DEADLINE ALERT : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options
NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) and reminds investors of the February 3, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jan 05, 2023 04:45 am ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Jan 04, 2023 07:00 am ET
Spectrum Pharmaceuticals Announces Management Changes
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately. The company’s clinical development function will be led by Dr. Shanta Chawla, Vice President, Clinical Development, also effective immediately. Dr. Chawla was the principal physician on the ROLVEDON™ (eflapegrastim-xnst) injection Phase 3 program and was instrumental in successfully navigati
Jan 04, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Jan 03, 2023 08:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-10677, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired
Jan 03, 2023 08:20 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
NEW YORK, Jan. 3, 2023 /PRNewswire/ --
Jan 03, 2023 10:00 am ET
GNRC, VERU & SPPI Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 02, 2023 07:30 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm– SPP
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the “Class Period”), of the...
Jan 01, 2023 04:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and...
Dec 30, 2022 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Dec. 30, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Dec 29, 2022 05:06 pm ET
SPECTRUM DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) and reminds investors of the February 3, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Dec 29, 2022 04:45 am ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Dec 28, 2022 05:18 pm ET
Class Action Involving Spectrum Pharmaceuticals, Inc. (SPPI): Contact Robbins LLP if You Incurred Significant Financial Harm from Your Investment in Spectrum Pharmaceuticals, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between December 6, 2021 and September 22, 2022, for violations of the...
Dec 28, 2022 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Dec. 28, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Dec 27, 2022 01:04 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
NEW YORK, Dec. 27, 2022 /PRNewswire/ --  
Dec 27, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 27, 2022, Spectrum’s Board of Directors granted an aggregate of 206,059 inducement restricted stock units (“RSUs”) to commercial non-executive employees who were hired specifically for the launch of ROLVEDON. The awards were granted under Spectrum’s 2022 Employment Inducement Incentive Award Plan (“Inducement Plan”) as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the gran
Dec 27, 2022 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Dec. 27, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Dec 26, 2022 12:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Dec. 26, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-10677, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired
Dec 25, 2022 08:08 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Acton Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and...
Dec 23, 2022 05:28 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the “Class Period”), of the...
Dec 22, 2022 05:06 pm ET
SPECTRUM DEADLINE ALERT
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options
Dec 22, 2022 04:45 am ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 22, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Dec 21, 2022 10:00 am ET
GNRC, VERU & SPPI Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 21, 2022 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Dec. 21, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Dec 20, 2022 06:07 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
NEW YORK, Dec. 20, 2022 /PRNewswire/ --
Dec 20, 2022 05:51 pm ET
Kaplan Fox Reminds Investors with Losses in Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) of Upcoming Lead Plaintiff Deadline
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) filed a proposed class action suit in the United States District Court for the Southern District of New York against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NasdaqGS: SPPI),...
Dec 20, 2022 04:45 am ET
SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders
NEW YORK, Dec. 20, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.
Dec 19, 2022 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK , Dec. 19, 2022 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders:
Dec 16, 2022 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Dec. 16, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Dec 15, 2022 05:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Dec 15, 2022 04:45 am ET
SPPI LAWSUIT ALERT: Levi & Korsinsky Notifies Spectrum Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit.
Dec 14, 2022 05:18 pm ET
Spectrum Pharmaceuticals, Inc. (SPPI) Equity Alert: Contact Robbins LLP for Information About the Class Action Against Spectrum Pharmaceuticals, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between December 6, 2021 and September 22, 2022, for violations of the...
Dec 14, 2022 04:53 pm ET
SPECTRUM DEADLINE ALERT
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options
Dec 14, 2022 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 3, 2023 - (NASDAQ: SPPI)
NEW YORK, Dec. 14, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spectrum Pharmaceuticals, Inc..
Dec 13, 2022 07:00 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 13, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ:SPPI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 13, 2022 06:07 pm ET
SPPI INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
NEW YORK, Dec. 13, 2022 /PRNewswire/ --
Dec 13, 2022 04:01 pm ET
GNRC, VERU & SPPI Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 13, 2022 03:00 pm ET
SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 3, 2023 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Shareholders
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.
Dec 13, 2022 12:29 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Dec 12, 2022 09:05 pm ET
SPPI EQUITY NOTICE: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than February 2, 2023.
Dec 12, 2022 08:00 pm ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 12, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ:SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 12, 2022 09:10 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Action and to Actively Participate
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spectrumcommon stock between December 6, 2021 through September 22, 2022, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/sppi.                       
Dec 12, 2022 09:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Action and to Actively Participate
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spectrumcommon stock between December 6, 2021 through September 22, 2022, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/sppi.                       
Dec 12, 2022 04:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spectrum Investors of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- Attention Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ: SPPI) shareholders:
Dec 12, 2022 01:18 am ET
Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between December 6, 2021 and September 22, 2022, for violations of the Securities Exchange Act of 1934. Spectrum purports to be a biopharmaceutical c
Dec 09, 2022 03:20 pm ET
National Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug Application
Complaint Alleges Spectrum Pharmaceuticals Failed to Disclose Negative Data from Clinical Trials
Dec 09, 2022 07:30 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 9, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ:SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 09, 2022 04:45 am ET
SPPI SHAREHOLDER ALERT: Jakubowitz Law Reminds Spectrum Shareholders of a Lead Plaintiff Deadline of February 3, 2023
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Dec 08, 2022 12:42 pm ET
Spectrum Pharmaceuticals, Inc. (SPPI) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Spectrum Pharmaceuticals, Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between December 6, 2021 and September 22, 2022, for violations of the...
Dec 08, 2022 09:02 am ET
SPECTRUM DEADLINE ALERT
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options
Dec 08, 2022 07:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 07, 2022 09:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Dec 07, 2022 09:37 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. (“Spectrum” or “the Company”) (NASDAQ:
Dec 07, 2022 12:10 am ET
INVESTOR DEADLINE ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in Spectrum Pharmaceuticals, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm
Dec 06, 2022 06:55 pm ET
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spectrum Pharmaceuticals, Inc. (SPPI)
The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between December 6, 2021 and September 22, 2022, for violations of the Securities Exchange Act of 1934. Spectrum purports to be a biopharmaceutical company fo
Dec 06, 2022 01:55 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in Spectrum Pharmaceuticals, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. (“Sepctrum” or “the Company”) (NASDAQ:
Dec 06, 2022 07:00 am ET
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) in oncology for Hematopoietic Growth Factors. The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN) and now include ROLVEDON as a treatment option under Management of Neutropenia: G-CSFs for Prophylaxis of Febrile Neutropenia and Mai
Dec 05, 2022 09:40 pm ET
Kaplan Fox Files Class Action to Recover Losses for Investors Who Purchased Common Stock of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI)
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a proposed class action suit in the United States District Court for the Southern District of New York against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NasdaqGS: SPPI),...
Dec 05, 2022 06:49 pm ET
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Dec 05, 2022 04:00 pm ET
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 5, 2022, Spectrum’s Board of Directors granted an aggregate of 736,988 inducement restricted stock units (“RSUs”) to commercial non-executive employees who were hired specifically for the launch of ROLVEDON. The awards were granted under Spectrum’s 2022 Employment Inducement Incentive Award Plan (“Inducement Plan”) as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant
Dec 02, 2022 08:50 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), F45 Training Holdings, Inc. (NYSE: FXLV), PROG Holdings, Inc. (NYSE: PRG),...
Dec 02, 2022 03:32 pm ET
Kaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) - INVESTOR UPDATE
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would...
Nov 29, 2022 03:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Nov 27, 2022 08:40 pm ET
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against against GrafTech International Ltd. (NYSE: EAF), Cantaloupe, Inc. (NASDAQ: CTLP, OTCMKTS: CTLPP), Spectrum Pharmaceuticals,...
Nov 25, 2022 10:59 am ET
Kaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) - INVESTOR UPDATE
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would...
Nov 25, 2022 06:00 am ET
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Spectrum’s New Drug Application (NDA) for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations. The FDA issued a CRL indicating the poziotinib application cannot be approved in its p
Nov 21, 2022 06:16 pm ET
Kaplan Fox Investigates Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to...
Nov 16, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against against GrafTech International Ltd. (NYSE: EAF), Cantaloupe, Inc. (NASDAQ: CTLP, OTCMKTS: CTLPP), Spectrum Pharmaceuticals,...
Nov 11, 2022 08:00 pm ET
SPPI Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Spectrum Pharmaceuticals, Inc.
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to...
Nov 10, 2022 04:05 pm ET
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended September 30, 2022 and provided a corporate update.
Nov 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cantaloupe, Inc. (NASDAQ: CTLP, OTCMKTS: CTLPP), EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), Spectrum Pharmaceuticals,...
Nov 03, 2022 05:16 pm ET
Spectrum Pharmaceuticals, Inc. Shareholder Alert: Kaplan Fox Investigates Potential Securities Fraud
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to...
Nov 03, 2022 07:00 am ET
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022, at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Nov 01, 2022 07:00 pm ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) resulting from allegations that Spectrum Pharmaceuticals may...
Oct 31, 2022 07:58 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - SPPI
NEW YORK, Oct. 31, 2022 /PRNewswire/ --
Oct 28, 2022 04:22 pm ET
EQUITY ALERT: Rosen Law Firm Encourages Spectrum Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) resulting from allegations that Spectrum Pharmaceuticals may have issued materially misleading business information to the investing public.
Oct 28, 2022 02:41 pm ET
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to...
Oct 21, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and UiPath and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), F45 Training Holdings, Inc. (NYSE: FXLV), PROG Holdings, Inc. (NYSE: PRG),...
Oct 21, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the commercial availability of ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. ROLVEDON received U.S. Food and Drug Administration approval in September 2022.
Oct 16, 2022 11:09 pm ET
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), F45 Training Holdings, Inc....
Oct 11, 2022 09:58 pm ET
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), and F45 Training Holdings,...
Oct 10, 2022 07:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
NEW YORK, Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 06, 2022 06:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Oct 02, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, Compass, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cantaloupe, Inc. (NASDAQ: CTLP, OTCMKTS: CTLPP), Compass Minerals International, Inc. (NYSE: CMP), and Spectrum...
Sep 29, 2022 09:51 pm ET
SPECTRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Spectrum Pharmaceuticals, Inc. on Behalf of Spectrum Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) on behalf of Spectrum stockholders. Our investigation concerns whether Spectrum has violated the federal securities laws and/or engaged in other unlawful business practices.
Sep 28, 2022 02:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Sep 23, 2022 04:21 pm ET
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to...
Sep 23, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it has entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC (SLR) for a term loan facility of up to $65 million. The Company believes this transaction, combined with Spectrum's existing cash balance, provides sufficient capital to optimize the commercial launch of ROLVEDON™ (eflapegrastim-xnst) injection, which received U.S. Food and Drug Administration (FDA)
Sep 22, 2022 03:30 pm ET
Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”) met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations. The committee voted 9-4 that the current benefits of poziotinib did not outweigh its risks.
Sep 13, 2022 10:45 am ET
Thinking about buying stock in Syros Pharmaceuticals, American Virtual Cloud Technologies, Spectrum Pharmaceuticals, Rivian Automotive, or Peloton Interactive?
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYRS, AVCT, SPPI, RIVN, and PTON.
Sep 12, 2022 08:30 am ET
Thinking about buying stock in Ventyx Biosciences, Aterian, Aditxt, RA Medical Systems, or Spectrum Pharmaceuticals?
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTYX, ATER, ADTX, RMED, and SPPI.
Sep 10, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC). The data show that poziotinib is highly active in G778 mutations in both treatment naïve and previously treated patients with NSCLC.
Sep 09, 2022 10:50 pm ET
SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI).
Sep 09, 2022 04:19 pm ET
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Sep 05, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer (NSCLC). The poster will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2022 that will take place in Paris from September 9-13, 2022.
Aug 26, 2022 10:50 pm ET
SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI
NEW ORLEANS, Aug. 26, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI). 
Aug 12, 2022 08:29 pm ET
SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI).
Aug 11, 2022 08:00 am ET
Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2022 and provided a corporate update.
Jul 29, 2022 07:00 am ET
Spectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific.
Jun 02, 2022 07:00 am ET
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences:
May 26, 2022 05:01 pm ET
Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced additional exploratory data for poziotinib in non-small cell lung cancer (NSCLC) patients harboring HER2 exon 20 insertion mutations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from June 3-7.
May 17, 2022 07:00 am ET
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26, 2022. A presentation will be available on the Investor Relations section of the company’s website at
May 12, 2022 04:00 pm ET
Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2022 and provided a corporate update.
May 11, 2022 07:00 am ET
Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum’s Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role.
May 06, 2022 07:00 am ET
Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Thursday, May 12, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
May 05, 2022 07:00 am ET
Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience.
Apr 11, 2022 09:31 am ET
Thinking about buying stock in Hoth Therapeutics, Spectrum Pharmaceuticals, Datto Holding, Bilibili, or Hycroft Mining?
NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, SPPI, MSP, BILI, and HYMC.
Apr 11, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA) for eflapegrastim has been accepted for filing. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) goal date of September 9, 2022. Spectrum is seeking an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically signifi
Apr 04, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022.
Mar 24, 2022 08:31 am ET
Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals?
NEW YORK, March 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKLA, HEPS, BVXV, TCOM, and SPPI.
Mar 24, 2022 08:30 am ET
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
PALM BEACH, Fla., March 24, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diagnosed with breast cancer across the globe, the need for accurate and efficient treatment outcomes for the patient remains unparalleled. Furthermore, the strong trend of continuous R&D amongst key market players engaged in breast cancer therapeutics would lead to the launch of breakthrough therapeutics in the coming year
Mar 21, 2022 09:31 am ET
Thinking about buying stock in BlackBerry, VEON, Ultrapar Participacoes, Spectrum Pharmaceuticals, or ThredUp?
NEW YORK, March 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, VEON, UGP, SPPI, and TDUP.
Mar 17, 2022 04:00 pm ET
Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2021.
Mar 11, 2022 07:00 am ET
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a corporate update on Thursday, March 17, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Mar 10, 2022 07:00 am ET
Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors.
Mar 07, 2022 06:00 am ET
Spectrum Pharmaceuticals Presents Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 Insertion Mutations
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial. This data is from 70 first-line patients with non-small lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16 mg daily, given as 16 mg once daily (48 patients) or 8 mg twice daily (22 patients) of oral poziotinib. These results showed a confirmed objective response rate (ORR) of 41% (95% CI:30%-54%), as evaluated centrally by an independent image
Feb 28, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on poziotinib at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2022 being held virtually March 7-8, 2022. Details of the presentation are as follows:
Feb 11, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been accepted for review by the U.S. Food and Drug Administration (FDA).
Jan 26, 2022 05:44 pm ET
Constellation Energy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Jan. 26, 2022 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600:
Jan 20, 2022 07:00 am ET
Spectrum Pharmaceuticals to Participate in B. Riley Securities 2022 Virtual Oncology Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A fireside chat is scheduled for Thursday, January 27, 2022 at 9:30 a.m. ET / 6:30 a.m. PT.
Jan 14, 2022 09:30 am ET
Thinking about buying stock in China SXT Pharmaceuticals, Virgin Galactic, Citigroup, Novavax, or Spectrum Pharmaceuticals?
NEW YORK, Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SXTC, SPCE, C, NVAX, and SPPI.
Jan 05, 2022 08:00 am ET
Spectrum Pharmaceuticals Announces Strategic Restructuring
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a strategic restructuring. The company will prioritize its late-stage product opportunities, poziotinib and ROLONTIS® (eflapegrastim), and will deprioritize development activities of its early-stage clinical development and research programs. The company has made these decisions following a detailed review of its operations, portfolio and growth opportunities, and will focus its resources accordingly.
Jan 04, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for ROLONTIS® (eflapegrastim) and poziotinib. Under the terms of the strategic investment, Hanmi entered into a $20 million equity purchase agreement that will be priced at $1.60 per share.
Dec 15, 2021 08:07 am ET
Did You Acquire (SPPI) Before December 27, 2018? Should Spectrum Pharmaceuticals Management be Held Accountable for Investors Losses? Contact Johnson Fistel
Johnson Fistel, LLP is investigating potential claims on behalf of Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) against certain of its officers and directors. Recently, a class action complaint was filed against...
Dec 06, 2021 07:00 am ET
Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it has submitted its New Drug Application (NDA) for poziotinib to the U.S. Food and Drug Administration (FDA) for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations. The NDA submission is based on the positive results of Cohort 2 from the ZENITH20 clinical trial, which assessed the safety and efficacy of poziotinib. The product has received Fast Track designation
Dec 01, 2021 04:00 pm ET
Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Tom Riga, currently Chief Commercial and Chief Operating Officer, will be the next President and CEO effective December 31, 2021. Mr. Riga will also join the company’s Board of Directors upon assuming his new role. Spectrum and Joseph Turgeon, President and CEO, have agreed that Mr. Turgeon will retire from Spectrum on December 31, 2021, after nine years with the company. Accordingly, he will also be stepping down from Spectrum’s Board of Directors
Nov 30, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in JMP Securities Hematology and Oncology Summit
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the JMP Securities Hematology and Oncology Summit, a virtual presentation is scheduled for Tuesday, December 7, 2021 at 2:40 p.m. ET / 11:40 a.m. PT.
Nov 11, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in 2021 Jefferies London Healthcare Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Jefferies London Healthcare Conference. A virtual fireside chat will be available to conference attendees, on-demand beginning on Thursday, November 18, 2021, at 3 a.m. ET / 8 a.m. GMT.
Nov 10, 2021 04:00 pm ET
Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced financial results for the three-month period ended September 30, 2021 and provided a corporate update.
Nov 03, 2021 07:00 am ET
Spectrum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2021 financial results and provide a corporate update on Wednesday, November 10, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More